Nonetheless, among these proteins, PDE9A is a druggable-target, which is currently in clinical trials for Alzheimer’s disease, while FPRs have been postulated as possible targets for mitigating ischemia-induced inflammation70,71. This evidence concerns the gene PDE9A and early-onset autosomal dominant Alzheimer disease.